The SME IPO market in India continues to attract strong investor attention, and the Q-Line Biotech IPO GMP today 2026 is becoming one of the most searched topics among IPO investors. With a strong grey market premium (GMP), growing subscription interest, and positive market sentiment, Q-Line Biotech IPO is currently gaining traction in the primary market.

In this article, we cover the Q-Line Biotech IPO GMP live updates, IPO dates, price band, subscription status, expected listing price, company overview, and complete review and analysis for investors.

Q-Line Biotech IPO Details 2026

Q-Line Biotech IPO is a book-built SME IPO issue worth approximately ₹214.48 crore. The IPO consists entirely of a fresh issue of shares, helping the company raise funds for business expansion and corporate purposes.

Q-Line Biotech IPO Important Dates

ParticularsDetails
IPO Opening DateMay 21, 2026
IPO Closing DateMay 25, 2026
Allotment DateMay 26, 2026
Refund InitiationMay 27, 2026
Shares Credit DateMay 27, 2026
Listing DateMay 29, 2026
Listing ExchangeNSE SME

Q-Line Biotech IPO Price Band and Lot Size

The company has fixed the IPO price band at ₹326 to ₹343 per share.

IPO InformationDetails
Face Value₹10 per share
Price Band₹326 – ₹343
Lot Size400 Shares
Minimum Retail Investment₹2,74,400
HNI Minimum Investment₹4,11,600
Issue TypeBook Build Issue
Total Issue Size₹214.48 Crore

The minimum investment amount is comparatively higher because investors must apply for at least two lots in the retail category.

Q-Line Biotech IPO GMP Today 2026

The Q-Line Biotech IPO GMP today 2026 indicates strong investor sentiment in the grey market. Grey market premium is an unofficial indicator showing expected listing gains before the stock gets listed on the exchange.

Q-Line Biotech SME IPO Day-wise GMP Trend

DateIPO PriceGMPExpected Listing PriceEstimated Gain
19 May 2026₹343₹95₹43827.70%
18 May 2026₹343₹69₹41220.12%
17 May 2026₹343₹0₹3430%

As per the latest Q-Line Biotech IPO grey market premium today, the GMP has increased significantly from ₹69 to ₹95, indicating positive market demand.

However, investors should remember that GMP is unofficial and can change rapidly depending on market conditions.

Q-Line Biotech IPO Expected Listing Price 2026

Based on the current GMP trend, the Q-Line Biotech IPO expected listing price 2026 is estimated around ₹430 to ₹440 per share.

If the current premium sustains till listing day, investors may expect decent listing gains. However, listing performance also depends on broader market sentiment, subscription demand, and institutional participation.

Estimated Listing Scenario

These figures are only estimates and actual listing prices may vary.

Q-Line Biotech IPO Subscription Status Today

The Q-Line Biotech IPO subscription status today will be closely watched by retail investors, HNIs, and SME market participants.

A strong subscription generally indicates:

Since the IPO opens on May 21, 2026, investors are expected to monitor category-wise subscription data daily for:

Strong subscription in the HNI category often boosts GMP momentum in SME IPOs.

Q-Line Biotech IPO Review and Analysis 2026

The Q-Line Biotech IPO review and analysis 2026 appears positive based on current market trends and GMP performance.

Positive Factors

Risk Factors

Investors should carefully evaluate company fundamentals, financials, business model, and risk appetite before applying.

Should You Apply for Q-Line Biotech IPO?

The strong Q-Line Biotech IPO GMP live updates indicate good investor interest in the IPO. The increasing grey market premium also reflects positive expectations regarding listing gains.

Short-term listing gain investors may find the IPO attractive due to:

Long-term investors should additionally analyze:

Final Thoughts

The Q-Line Biotech IPO GMP today 2026 continues to remain strong ahead of the IPO opening date. With a latest GMP of around ₹95 and an estimated listing price near ₹438, market sentiment currently appears positive.

The IPO will open for subscription from May 21 to May 25, 2026, and is expected to list on NSE SME on May 29, 2026.

Investors should keep tracking:

As always, IPO investments carry risks, and GMP should not be the only factor considered before investing.

⚠️ Disclaimer

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. This is only for informational purposes.

Angel One Ltd. is just acting as the distributor of the IPO. Investors are requested to do their due diligence before investing in any IPO. Investor grievance redressal mechanism of exchange would not be available for applying in IPO

📍 Registration Details

Angel One Limited (formerly known as Angel Broking Limited), Registered Office: 601, 6th Floor, Ackruti Star, Central Road, MIDC, Andheri East, Mumbai – 400093.
Tel: 080-47480048
CIN: L67120MH1996PLC101709
SEBI Regn. No.: INZ000161534

Compliance Officer: Mr. Bineet Jha
Tel: (022) 39413940
Email: compliance@angelbroking.com


📞 Contact 4R Investments

📍 3-1-309/310, Tara Kaushalya Nivas, Nimboliadda, Kachiguda, Hyderabad – 500027
📞 6300169336
📧 contact@4rinvestments.in
🌐 https://4rinvestments.in/

Leave a Reply

Your email address will not be published. Required fields are marked *